s 55746
Follicular Lymphoma, Mantle Cell Lymphoma
Novartis PharmaceuticalsSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Follicular Lymphoma, Mantle Cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Idelalisib Novartis Pharmaceuticals | Phase 1 | CC |
Same molecule, other indications
s 55746 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →